SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNLX - NanoLogix, Incorporated
NNLX 0.00010000.0%Oct 31 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: kphone6/1/2017 12:28:33 PM
   of 78
 

Nanologix Incorporated











NanoLogix TB Detection Technology Use on Africa Project Increases

?



?

NanoLogix is pleased to announce that this week they shipped a new order fortheir TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.



This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.



For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:



https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html



Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."




Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext